SARS-COV-2 is a strain of coronavirus that causes severe respiratory illness. The virus enters cells via the human ACE2 (ACE2) receptor via the viral spike protein (s-protein)1. This key interaction of viral entry through ACE2 allows the virus to hijack the cellular replication machinery, overload the patient’s immune system, and can cause death in severe cases.

​

Our company specializes in life sciences consulting with in-house capabilities in therapeutic protein design and drug development. We are currently developing a unique anti-COVID-19 (SARS-COV-2) biologics platform, from which lead compounds for a novel coronavirus blocking combinatorial therapy have been generated.

​

Our novel SARS-COV-2 blocking combinatorial therapy built by our proprietary in-silico modeling platform works in tandem to inhibit SARS-COV-2 viral entry and to block viral replication if the virus is already inside a patient’s cells. This front-line therapy is advantageous because it can be used immediately when a patient is infected with the virus. This is in stark contrast to vaccines which require the patient to have an uncompromised immune system and can take up to 6 weeks to be efficacious.

​

Moreover, this in-silico biological platform can easily be leveraged to make high affinity blockers to other genetic cousins of SARS-COV-2 such as MERS-COV. In fact, we already have in-silico MERS-COV inhibitors in our pipeline that are ready for validation as future therapeutics.

​

Our work has passed Phase I of both NIH ACTIV, NSF SBIR grant review, and we are currently actively evaluating partnerships with biotech, pharma and other research institutes. If interested in partnership discussions, please contact us.